<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Complement Altern Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Complement Altern Med</journal-id><journal-title-group><journal-title>BMC Complementary and Alternative Medicine</journal-title></journal-title-group><issn pub-type="epub">1472-6882</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3373729</article-id><article-id pub-id-type="publisher-id">1472-6882-12-S1-O27</article-id><article-id pub-id-type="doi">10.1186/1472-6882-12-S1-O27</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>OA07.03. Randomized, double-blind, double-dummy trial of myrrh, chamomile, coffee charcoal compared to mesalazine in maintaining remission in ulcerative colitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Langhorst</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Westendorf</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Knopp</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Schneider</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Goos</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Albrecht</surname><given-names>U</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Rueffer</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Stange</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Michalsen</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Dobos</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>University of Duisburg, Complementary and Integrative Medicine, Essen, Germany</aff><aff id="I2"><label>2</label>Department for Microbiology, University of Duisburg-Essen, Essen, Germany</aff><aff id="I3"><label>3</label>Biometric Institute, University of Hannover, Hannover, Germany</aff><aff id="I4"><label>4</label>Repha GmbH, Hannover, Germany</aff><aff id="I5"><label>5</label>Mediconomics, Hannover, Germany</aff><aff id="I6"><label>6</label>Enterosan, L+S Labor, Bad Bocklet - Grossenbrach, Germany</aff><aff id="I7"><label>7</label>Immanuel Hospital, Charit&#x000e9;, Berlin, Germany</aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2012</year></pub-date><volume>12</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Scientific Abstracts Presented at the International Research Congress on Integrative Medicine and Health 2012</named-content><named-content content-type="supplement-editor">Robert Saper and David Eisenberg</named-content><named-content content-type="supplement-sponsor">This conference and proceedings were supported by Grant Number R13AT007128 from the National Center for Complementary and Alternative Medicine. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Complementary and Alternative Medicine or the National Institutes of Health.</named-content></supplement><fpage>O27</fpage><lpage>O27</lpage><permissions><copyright-statement>Copyright &#x000a9;2012 Langhorst et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Langhorst et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1472-6882/12/S1/O27"/><conference><conf-date>15-18 May 2012</conf-date><conf-name>International Research Congress on Integrative Medicine and Health 2012</conf-name><conf-loc>Portland, Oregon, USA</conf-loc></conference></article-meta></front><body><sec><title>Purpose</title><p>We compared the efficacy of the herbal preparation of myrrh, chamomile extract and coffee charcoal (herb) with a mesalazine (mes) therapy in maintaining remission in ulcerative colitis (UC).</p></sec><sec sec-type="methods"><title>Methods</title><p>A total of 96 patients (51 female) with UC in remission (not longer than 12 months) were included in a randomized, double-blind, double-dummy, multicenter, non inferiority study comparing mesalazine 500 mg (3x1/d) to 100mg myrrh, 70mg chamomile extract and 50mg coffee charcoal (3 x 4/d) over a time period of 12 months. As primary outcome criterion, non-inferiority of the herbal preparation was defined and accepted, if the difference in the colitis activity index (Colitis Activity Index - CAI - Rachmilewitz) (calculated at six time points during the 12 month interval) averaged over all visits was &#x02264; 1 point. Furthermore, relapse rates, relapse-free times, safety, a comprehensive activity index (CAI, CRP and fecal Lactoferrin, Calprotectin and PMN-Elastasis), an endoscopic activity index and Health-related Quality of life (HrQoL) were assessed. Peripheral CD4+CD25+ reg T-cells were investigated in a subgroup at each time point and during a flare.</p></sec><sec sec-type="results"><title>Results</title><p>Primary outcome criterion (p = 0.19), relapse rates (CAI&#x0003e;4) (mes 22/49 patients vs herb 25/47 patients; p = 0.54), relapse-free time (268 &#x000b1; 22 days for mes and 240 &#x000b1; 23 days (p = 0.40) for the herb), the comprehensive activity index and HrQoL did not show a significant difference. Of notice, peripheral CD4+CD25+ regulatory T-cells showed a distinct different pattern at time points pre-flare and flare for the two treatment modalities (CD4+CD25+T<sub>reg</sub> mes p=non significant (ns); herb p=0.02; CD4+CD25+ T<sub>reg</sub> high mes p=ns; herb p=0.008).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The herbal preparation shows efficacy and safety in maintaining remission non-inferior to mesalazine in ulcerative colitis. It appears to offer an alternative option for maintenance therapy. Regulatory T-cell pattern might give first evidence to suggest a different mechanism of action.</p></sec></body></article>